Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy.
Cancer
Computational tools
Drug repositioning
Drug repurposing
Immunotherapy
Non-oncologic drugs
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
23 Apr 2024
23 Apr 2024
Historique:
received:
22
01
2024
accepted:
20
03
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
23
4
2024
Statut:
epublish
Résumé
Drug repositioning or repurposing has gained worldwide attention as a plausible way to search for novel molecules for the treatment of particular diseases or disorders. Drug repurposing essentially refers to uncovering approved or failed compounds for use in various diseases. Cancer is a deadly disease and leading cause of mortality. The search for approved non-oncologic drugs for cancer treatment involved in silico modeling, databases, and literature searches. In this review, we provide a concise account of the existing non-oncologic drug molecules and their therapeutic potential in chemotherapy. The mechanisms and modes of action of the repurposed drugs using computational techniques are also highlighted. Furthermore, we discuss potential targets, critical pathways, and highlight in detail the different challenges pertaining to drug repositioning for cancer immunotherapy.
Identifiants
pubmed: 38652344
doi: 10.1007/s12032-024-02368-8
pii: 10.1007/s12032-024-02368-8
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
122Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, Jyoti kumar V, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell Int. 2021;21(1):499. https://doi.org/10.1186/s12935-021-02202-5 .
doi: 10.1186/s12935-021-02202-5
pubmed: 34535145
pmcid: 8447515
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 .
doi: 10.3322/caac.21660
pubmed: 33538338
Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, et al. Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions. Acta Pharm Sin B. 2022;12(2):532–57. https://doi.org/10.1016/j.apsb.2021.09.006 .
doi: 10.1016/j.apsb.2021.09.006
pubmed: 35256933
Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177(11):1569–75. https://doi.org/10.1001/jamainternmed.2017.3601 .
doi: 10.1001/jamainternmed.2017.3601
pubmed: 28892524
pmcid: 5710275
Kaushik I, Ramachandran S, Prasad S, Srivastava SK. Drug rechanneling: a novel paradigm for cancer treatment. Semin Cancer Biol. 2021;68:279–90. https://doi.org/10.1016/j.semcancer.2020.03.011 .
doi: 10.1016/j.semcancer.2020.03.011
pubmed: 32437876
Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: Old weapon for new battle. Semin Cancer Biol. 2021;68:8–20. https://doi.org/10.1016/j.semcancer.2019.09.012 .
doi: 10.1016/j.semcancer.2019.09.012
pubmed: 31550502
Basso J, Miranda A, Sousa J, Pais A, Vitorino C. Repurposing drugs for glioblastoma: from bench to bedside. Cancer Lett. 2018;428:173–83. https://doi.org/10.1016/j.canlet.2018.04.039 .
doi: 10.1016/j.canlet.2018.04.039
pubmed: 29729291
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–83. https://doi.org/10.1182/blood-2016-09-736686 .
doi: 10.1182/blood-2016-09-736686
pubmed: 28003274
pmcid: 5413297
Dimopoulos MA, Kastritis E. Thalidomide for myeloma: still here? Lancet Haematol. 2018;5(10):e439–40. https://doi.org/10.1016/S2352-3026(18)30154-6 .
doi: 10.1016/S2352-3026(18)30154-6
pubmed: 30290901
Liu Q, Tong D, Liu G, Gao J, Wang LA, Xu J, et al. Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration. Clin Cancer Res. 2018;24(22):5622–34. https://doi.org/10.1158/1078-0432.CCR-18-0420 .
doi: 10.1158/1078-0432.CCR-18-0420
pubmed: 30012567
Raju TN. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). The Lancet. 2000;355(9208):1022. https://doi.org/10.1016/s0140-6736(05)74775-9 .
doi: 10.1016/s0140-6736(05)74775-9
Kresge N, Simoni RD, Hill RL. The rational design of nucleic acid inhibitors to treat leukemia: the work of George H. Hitchings. J Biol Chem. 2008;283(18):e10–11.
doi: 10.1016/S0021-9258(20)49286-5
Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993–6. https://doi.org/10.1038/nrd2199 .
doi: 10.1038/nrd2199
pubmed: 17139284
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201. https://doi.org/10.1038/s41392-021-00572-w .
doi: 10.1038/s41392-021-00572-w
pubmed: 34054126
pmcid: 8165101
Gonzalez-Fierro A, Dueñas-González A. Drug repurposing for cancer therapy, easier said than done. Semin Cancer Biol. 2021;68:123–31. https://doi.org/10.1016/j.semcancer.2019.12.012 .
doi: 10.1016/j.semcancer.2019.12.012
pubmed: 31877340
Medema MH, Fischbach MA. Computational approaches to natural product discovery. Nat Chem Biol. 2015;11(9):639–48. https://doi.org/10.1038/nchembio.1884 .
doi: 10.1038/nchembio.1884
pubmed: 26284671
pmcid: 5024737
Baltz RH. Natural product drug discovery in the genomic era: realities, conjectures, misconceptions, and opportunities. J Ind Microbiol Biotechnol. 2019;46(3–4):281–99. https://doi.org/10.1007/s10295-018-2115-4 .
doi: 10.1007/s10295-018-2115-4
pubmed: 30484124
Hur M, Campbell AA, Almeida-de-Macedo M, Li L, Ransom N, Jose A, et al. A global approach to analysis and interpretation of metabolic data for plant natural product discovery. Nat Prod Rep. 2013;30(4):565–83. https://doi.org/10.1039/c3np20111b .
doi: 10.1039/c3np20111b
pubmed: 23447050
pmcid: 3629923
Biermann F, Wenski SL, Helfrich EJN. Navigating and expanding the roadmap of natural product genome mining tools. Beilstein J Org Chem. 2022;18:1656–71. https://doi.org/10.3762/bjoc.18.178 .
doi: 10.3762/bjoc.18.178
pubmed: 36570563
pmcid: 9749553
Cui W, Aouidate A, Wang S, Yu Q, Li Y, Yuan S. Discovering anti-cancer drugs via computational methods. Front Pharmacol. 2020;11:733. https://doi.org/10.3389/fphar.2020.00733 .
doi: 10.3389/fphar.2020.00733
pubmed: 32508653
pmcid: 7251168
Prada-Gracia D, Huerta-Yépez S, Moreno-Vargas LM. Application of computational methods for anticancer drug discovery, design, and optimization. Bol Med Hosp Infant Mex. 2016;73(6):411–23. https://doi.org/10.1016/j.bmhimx.2016.10.006 .
doi: 10.1016/j.bmhimx.2016.10.006
pubmed: 29421286
pmcid: 7110968
Baldi A. Computational approaches for drug design and discovery: an overview. Syst Rev Pharm. 2010;1(1):99–105. https://doi.org/10.4103/0975-8453.59519 .
doi: 10.4103/0975-8453.59519
Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: a comprehensive review. South Asian J Cancer. 2013;2(2):91–97. https://doi.org/10.4103/2278-330X.110506 .
doi: 10.4103/2278-330X.110506
pubmed: 24455567
pmcid: 3876666
Selassie C, Verma RP. History of quantitative structure-activity relationships. Burger’s Med Chem Drug Discov. 2003;1:1–48. https://doi.org/10.1002/0471266949.bmc001.pub2 .
doi: 10.1002/0471266949.bmc001.pub2
Mendenhall J, Meiler J. Improving quantitative structure-activity relationship models using Artificial Neural Networks trained with dropout. J Comput Aided Mol Des. 2016;30(2):177–89. https://doi.org/10.1007/s10822-016-9895-2 .
doi: 10.1007/s10822-016-9895-2
pubmed: 26830599
pmcid: 4798928
Esposito EX, Hopfinger AJ, Madura JD. Methods for applying the quantitative structure-activity relationship paradigm. Methods Mol Biol. 2004;275:131–214. https://doi.org/10.1385/1-59259-802-1:131 .
doi: 10.1385/1-59259-802-1:131
pubmed: 15141113
Morris GM, Lim-Wilby M. Molecular docking. Methods Mol Biol. 2008;443:365–82. https://doi.org/10.1007/978-1-59745-177-2_19 .
doi: 10.1007/978-1-59745-177-2_19
pubmed: 18446297
Fan J, Fu A, Zhang L. Progress in molecular docking. Quant Biol. 2019;7:83–9. https://doi.org/10.1007/s40484-019-0172-y .
doi: 10.1007/s40484-019-0172-y
Yuriev E, Ramsland PA. Latest developments in molecular docking: 2010-2011 in review. J Mol Recognit. 2013;26(5):215–39. https://doi.org/10.1002/jmr.2266 .
doi: 10.1002/jmr.2266
pubmed: 23526775
Dias R, de Azevedo Jr WF. Molecular docking algorithms. Curr Drug Targets. 2008;9(12):1040–7. https://doi.org/10.2174/138945008786949432 .
doi: 10.2174/138945008786949432
pubmed: 19128213
Bhattarai D, Singh S, Jang Y, Hyeon Han S, Lee K, Choi Y. An insight into drug repositioning for the development of novel anti-cancer drugs. Curr Top Med Chem. 2016;16(19):2156–68. https://doi.org/10.2174/1568026616666160216153618 .
doi: 10.2174/1568026616666160216153618
pubmed: 26881715
Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5(1):113. https://doi.org/10.1038/s41392-020-00213-8 .
doi: 10.1038/s41392-020-00213-8
pubmed: 32616710
pmcid: 7331117
Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol. 2010;65(5):895–902. https://doi.org/10.1007/s00280-009-1095-5 .
doi: 10.1007/s00280-009-1095-5
pubmed: 19690861
Zhou X, Sun WJ, Wang WM, Chen K, Zheng JH, Lu MD, et al. Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anticancer Drugs. 2013;24(9):920–7. https://doi.org/10.1097/CAD.0b013e328364a109 .
doi: 10.1097/CAD.0b013e328364a109
pubmed: 23958790
Jiang W, Huang Y, Wang JP, Yu XY, Zhang LY. The synergistic anticancer effect of artesunate combined with allicin in osteosarcoma cell line in vitro and in vivo. Asian Pac J Cancer Prev. 2013;14(8):4615–9. https://doi.org/10.7314/apjcp.2013.14.8.4615 .
doi: 10.7314/apjcp.2013.14.8.4615
pubmed: 24083713
Wang Q, Wu LM, Li AY, Zhao Y, Wang NP. Experimental studies of antitumor effect of artesunate on liver cancer. Zhongguo Zhong Yao Za Zhi. 2001;26(10):707–8, 720 (Chinese).
pubmed: 12776323
Freire Boullosa L, Van Loenhout J, Flieswasser T, De Waele J, Hermans C, Lambrechts H, et al. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. Redox Biol. 2021;42:101949. https://doi.org/10.1016/j.redox.2021.101949 .
doi: 10.1016/j.redox.2021.101949
pubmed: 33812801
pmcid: 8113045
Cui XY, Park SH, Park WH. Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspase-dependent apoptosis. Oncol Rep. 2020;44(6):2715–24. https://doi.org/10.3892/or.2020.7818 .
doi: 10.3892/or.2020.7818
pubmed: 33125149
Pearson K, Jensen H, Kander T, Schött U. Desmopressin in vitro effects on platelet function, monitored with Multiplate, ROTEM and Sonoclot. Scand J Clin Lab Investig. 2016;76(4):282–90. https://doi.org/10.3109/00365513.2016.1149615 .
doi: 10.3109/00365513.2016.1149615
Benavente MA, Bianchi CP, Imperiale F, Aba MA. Antiproliferative effects of oxytocin and desmopressin on canine mammary cancer cells. Front Vet Sci. 2016;3:119. https://doi.org/10.3389/fvets.2016.00119 .
doi: 10.3389/fvets.2016.00119
pubmed: 28083539
pmcid: 5183597
Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, et al. Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic Clin Pharmacol Toxicol. 2013;112(1):63–69. https://doi.org/10.1111/j.1742-7843.2012.00923.x .
doi: 10.1111/j.1742-7843.2012.00923.x
pubmed: 22762560
Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56(1):47–60. https://doi.org/10.1016/j.critrevonc.2004.09.009 .
doi: 10.1016/j.critrevonc.2004.09.009
pubmed: 16039868
Imrali A, Mao X, Yeste-Velasco M, Shamash J, Lu Y. Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. Am J Cancer Res. 2016;6(8):1772–84.
pubmed: 27648364
pmcid: 5004078
Gruppuso PA, Boylan JM, Sanders JA. The physiology and pathophysiology of rapamycin resistance: implications for cancer. Cell Cycle. 2011;10(7):1050–8. https://doi.org/10.4161/cc.10.7.15230 .
doi: 10.4161/cc.10.7.15230
pubmed: 21389767
pmcid: 3100882
Fuchs R, Stracke A, Holzmann V, Luschin-Ebengreuth G, Meier-Allard N, Ebner N, et al. Prazosin induced lysosomal tubulation interferes with cytokinesis and the endocytic sorting of the tumour antigen CD98hc. Biochim Biophys Acta Mol Cell Res. 2018;1865(9):1211–29. https://doi.org/10.1016/j.bbamcr.2018.06.006 .
doi: 10.1016/j.bbamcr.2018.06.006
pubmed: 29909287
An M, Ma WH, Jia HW, Li YW, Feng JJ, Meng J, et al. Prazosin inhibits the growth and mobility of osteosarcoma cells. Transl Cancer Res. 2019;8(5):1997–2004. https://doi.org/10.21037/tcr.2019.09.03 .
doi: 10.21037/tcr.2019.09.03
pubmed: 35116948
pmcid: 8797549
Guo YC, Chang CM, Hsu WL, Chiu SJ, Tsai YT, Chou YH, et al. Indomethacin inhibits cancer cell migration via attenuation of cellular calcium mobilization. Molecules. 2013;18(6):6584–96. https://doi.org/10.3390/molecules18066584 .
doi: 10.3390/molecules18066584
pubmed: 23736792
pmcid: 6269835
Wang Z, Chen Y, Zheng R, Qin D, Chen X, Wang Y, et al. In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer. Prostaglandins. 1997;54(5):769–79. https://doi.org/10.1016/s0090-6980(97)00161-5 .
doi: 10.1016/s0090-6980(97)00161-5
pubmed: 9491207
Tilaoui M, Mouse HA, Jaafari A, Zyad A. Differential effect of artemisinin against cancer cell lines. Nat Prod Bioprospect. 2014;4(3):189–96. https://doi.org/10.1007/s13659-014-0024-4 .
doi: 10.1007/s13659-014-0024-4
pubmed: 24955301
pmcid: 4050314
Wong YK, Xu C, Kalesh KA, He Y, Lin Q, Wong WSF, et al. Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action. Med Res Rev. 2017;37(6):1492–517. https://doi.org/10.1002/med.21446 .
doi: 10.1002/med.21446
pubmed: 28643446
Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 2013;73(1):3–7. https://doi.org/10.1158/0008-5472.CAN-12-2464 .
doi: 10.1158/0008-5472.CAN-12-2464
pubmed: 23288916
Ciftci H, Sever B, Ocak F, Bayrak N, Yıldız M, Yıldırım H, et al. In vitro and in silico study of analogs of plant product plastoquinone to be effective in colorectal cancer treatment. Molecules. 2022;27(3):693. https://doi.org/10.3390/molecules27030693 .
doi: 10.3390/molecules27030693
pubmed: 35163957
pmcid: 8839215
Chen YH, Wu JX, Yang SF, Chen ML, Chen TH, Hsiao YH. Metformin potentiates the anticancer effect of everolimus on cervical cancer in vitro and in vivo. Cancers (Basel). 2021;13(18):4612. https://doi.org/10.3390/cancers13184612 .
doi: 10.3390/cancers13184612
pubmed: 34572837
Mussin N, Oh SC, Lee KW, Park MY, Seo S, Yi NJ, et al. Sirolimus and metformin synergistically inhibits colon cancer in vitro and in vivo. J Korean Med Sci. 2017;32(9):1385–95. https://doi.org/10.3346/jkms.2017.32.9.1385 .
doi: 10.3346/jkms.2017.32.9.1385
pubmed: 28776332
pmcid: 5546956
Wiggins HL, Wymant JM, Solfa F, Hiscox SE, Taylor KM, Westwell AD, et al. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochem Pharmacol. 2015;93(3):332–42. https://doi.org/10.1016/j.bcp.2014.12.014 .
doi: 10.1016/j.bcp.2014.12.014
pubmed: 25557293
pmcid: 4318799
Deng K, Shen J, Wang W, Li M, Li H, Chen C, et al. Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer. Cancer Biol Ther. 2019;20(1):52–64. https://doi.org/10.1080/15384047.2018.1504723 .
doi: 10.1080/15384047.2018.1504723
pubmed: 30183476
Wang Y, Ma Q, Zhang S, Liu H, Zhao B, Du B, et al. Digoxin enhances the anticancer effect on non-small cell lung cancer while reducing the cardiotoxicity of adriamycin. Front Pharmacol. 2020;11:186. https://doi.org/10.3389/fphar.2020.00186 .
doi: 10.3389/fphar.2020.00186
pubmed: 32180730
pmcid: 7059749
Das S, Tripathi N, Preet R, Siddharth S, Nayak A, Bharatam PV, et al. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade. Oncotarget. 2017;8(1):248–67. https://doi.org/10.18632/oncotarget.11335 .
doi: 10.18632/oncotarget.11335
pubmed: 27542249
Samanta A, Ravindran G, Sarkar A. Quinacrine causes apoptosis in human cancer cell lines through caspase-mediated pathway and regulation of small-GTPase. J Biosci. 2020;45:43. https://doi.org/10.1007/s12038-020-0011-3 .
doi: 10.1007/s12038-020-0011-3
pubmed: 32098922
Montgomery A, Adeyeni T, San K, Heuertz RM, Ezekiel UR. Curcumin sensitizes silymarin to exert synergistic anticancer activity in colon cancer cells. J Cancer. 2016;7(10):1250–7. https://doi.org/10.7150/jca.15690 .
doi: 10.7150/jca.15690
pubmed: 27390600
pmcid: 4934033
Sufi SA, Adigopula LN, Syed SB, Mukherjee V, Coumar MS, Rao HS, et al. In-silico and in-vitro anti-cancer potential of a curcumin analogue (1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione. Biomed Pharmacother. 2017;85:389–98. https://doi.org/10.1016/j.biopha.2016.11.040 .
doi: 10.1016/j.biopha.2016.11.040
pubmed: 27889234
Saeed MEM, Yücer R, Dawood M, Hegazy MF, Drif A, Ooko E, et al. In silico and in vitro screening of 50 curcumin compounds as EGFR and NF-κB inhibitors. Int J Mol Sci. 2022;23(7):3966. https://doi.org/10.3390/ijms23073966 .
doi: 10.3390/ijms23073966
pubmed: 35409325
pmcid: 9000198
Toden S, Tran HM, Tovar-Camargo OA, Okugawa Y, Goel A. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget. 2016;7(13):16158–71. https://doi.org/10.18632/oncotarget.7567 .
doi: 10.18632/oncotarget.7567
pubmed: 26930714
pmcid: 4941304
Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling. Anticancer Res. 2015;35(1):39–46.
pubmed: 25550533
pmcid: 4290892
Chatterjee K, AlSharif D, Mazza C, Syar P, Al Sharif M, Fata JE. Resveratrol and pterostilbene exhibit anticancer properties involving the downregulation of HPV oncoprotein E6 in cervical cancer cells. Nutrients. 2018;10(2):243. https://doi.org/10.3390/nu10020243 .
doi: 10.3390/nu10020243
pubmed: 29485619
pmcid: 5852819
Carter LG, D’Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014;21(3):R209–25. https://doi.org/10.1530/ERC-13-0171 .
doi: 10.1530/ERC-13-0171
pubmed: 24500760
pmcid: 4013237
Oliveira PM, Lopes TZ, Tedesco AC, Rahal P, Calmon MF. Effect of berberine associated with photodynamic therapy in cell lines. Photodiagn Photodyn Ther. 2020;32:102045. https://doi.org/10.1016/j.pdpdt.2020.102045 .
doi: 10.1016/j.pdpdt.2020.102045
Aleissa MS, Al-Zharani M, Alneghery LM, Aleissa AM. Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3). Saudi Pharm J. 2023;31(1):110–8. https://doi.org/10.1016/j.jsps.2022.11.009 .
doi: 10.1016/j.jsps.2022.11.009
pubmed: 36685297
Liu X, Ji Q, Ye N, Sui H, Zhou L, Zhu H, et al. Berberine inhibits invasion and metastasis of colorectal cancer cells via COX-2/PGE2 mediated JAK2/STAT3 signaling pathway. PLoS ONE. 2015;10(5):e0123478. https://doi.org/10.1371/journal.pone.0123478 .
doi: 10.1371/journal.pone.0123478
pubmed: 25954974
pmcid: 4425560
Wang K, Zhang C, Bao J, Jia X, Liang Y, Wang X, et al. Synergistic chemopreventive effects of curcumin and berberine on human breast cancer cells through induction of apoptosis and autophagic cell death. Sci Rep. 2016;6:26064. https://doi.org/10.1038/srep26064 .
doi: 10.1038/srep26064
pubmed: 27263652
pmcid: 4893614
Qu H, Song X, Song Z, Jiang X, Gao X, Bai L, et al. Berberine reduces temozolomide resistance by inducing autophagy via the ERK1/2 signaling pathway in glioblastoma. Cancer Cell Int. 2020;20(1):592. https://doi.org/10.1186/s12935-020-01693-y .
doi: 10.1186/s12935-020-01693-y
pubmed: 33298057
pmcid: 7727240
Samadi P, Sarvarian P, Gholipour E, Asenjan KS, Aghebati-Maleki L, Motavalli R, et al. Berberine: a novel therapeutic strategy for cancer. IUBMB Life. 2020;72(10):2065–79. https://doi.org/10.1002/iub.2350 .
doi: 10.1002/iub.2350
pubmed: 32735398
Choi SB, Bae GS, Jo IJ, Song HJ, Park SJ. Effects of berberine on acute necrotizing pancreatitis and associated lung injury. Pancreas. 2017;46(8):1046–55. https://doi.org/10.1097/MPA.0000000000000877 .
doi: 10.1097/MPA.0000000000000877
pubmed: 28797013
Spagnuolo C, Russo GL, Orhan IE, Habtemariam S, Daglia M, Sureda A, et al. Genistein and cancer: current status, challenges, and future directions. Adv Nutr. 2015;6(4):408–19. https://doi.org/10.3945/an.114.008052 .
doi: 10.3945/an.114.008052
pubmed: 26178025
pmcid: 4496735
Zhou S, Wu H, Ning W, Wu X, Xu X, Ma Y, et al. Ivermectin has new application in inhibiting colorectal cancer cell growth. Front Pharmacol. 2021;12:717529. https://doi.org/10.3389/fphar.2021.717529 .
doi: 10.3389/fphar.2021.717529
pubmed: 34483925
pmcid: 8415024
Dominguez-Gomez G, Chavez-Blanco A, Medina-Franco JL, Saldivar-Gonzalez F, Flores-Torrontegui Y, Juarez M, et al. Ivermectin as an inhibitor of cancer stem-like cells. Mol Med Rep. 2018;17(2):3397–403. https://doi.org/10.3892/mmr.2017.8231 .
doi: 10.3892/mmr.2017.8231
pubmed: 29257278
Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011;71(21):6764–72. https://doi.org/10.1158/0008-5472.CAN-11-0691 .
doi: 10.1158/0008-5472.CAN-11-0691
pubmed: 21896639
pmcid: 3206167
Lan K, Yan R, Zhu K, Li W, Xu Z, Dang C, et al. Itraconazole inhibits the proliferation of gastric cancer cells in vitro and improves patient survival. Oncol Lett. 2018;16(3):3651–7. https://doi.org/10.3892/ol.2018.9072 .
doi: 10.3892/ol.2018.9072
pubmed: 30127974
pmcid: 6096255
Barbosa EJ, Löbenberg R, de Araujo GLB, Bou-Chacra NA. Niclosamide repositioning for treating cancer: challenges and nano-based drug delivery opportunities. Eur J Pharm Biopharm. 2019;141:58–69. https://doi.org/10.1016/j.ejpb.2019.05.004 .
doi: 10.1016/j.ejpb.2019.05.004
pubmed: 31078739
Shangguan F, Liu Y, Ma L, Qu G, Lv Q, An J, et al. Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics. J Cancer. 2020;11(12):3454–66. https://doi.org/10.7150/jca.41418 .
doi: 10.7150/jca.41418
pubmed: 32284741
pmcid: 7150452
Gold A, Eini L, Nissim-Rafinia M, Viner R, Ezer S, Erez K, et al. Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response. Oncogene. 2019;38(17):3103–18. https://doi.org/10.1038/s41388-018-0654-9 .
doi: 10.1038/s41388-018-0654-9
pubmed: 30622338
Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28(9):513–27. https://doi.org/10.1038/s41434-021-00246-w .
doi: 10.1038/s41434-021-00246-w
pubmed: 33753909
pmcid: 8455322
Pantziarka P, Verbaanderd C, Sukhatme V, Rica Capistrano I, Crispino S, Gyawali B, et al. ReDO_DB: the repurposing drugs in oncology database. Ecancermedicalscience. 2018;6(12):886. https://doi.org/10.3332/ecancer.2018.886 .
doi: 10.3332/ecancer.2018.886
Rajkumar SV. Thalidomide in multiple myeloma. Oncology (Williston Park). 2000;14(12 Suppl 13):11–6.
pubmed: 11204667
Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016;127(9):1109–16. https://doi.org/10.1182/blood-2015-11-679415 .
doi: 10.1182/blood-2015-11-679415
pubmed: 26802176